Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently Vaccinated Individuals

Jaganathan, Soumya; Stieber, Francis; Rao, Sonia N.; Nikolayevskyy, Vladyslav; Manissero, Davide; Allen, Nadia; Boyle, Jeff; Howard, Jenny

doi:10.21203/rs.3.rs-623620/v1

Cited by 8 publications

(15 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study showed that T cell responses were detected on day 15 following the first dose of the vaccination, similar to the antibody responses. This early induction of T cell p. 18 responses agrees with the findings of a cohort study of 20 Singapore healthcare workers who received the BNT162b2 vaccine 7 , and a study of individuals who received the Moderna mRNA-1273 vaccine 14 . Notably, we observed that T cell responses were detectable earlier than the neutralizing antibodies, consistent with a previous report 7 .…”

Section: P 17supporting

confidence: 86%

See 1 more Smart Citation

SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: A 9 months longitudinal study

Takeuchi

Fukunaga

Yamamoto

et al. 2021

Preprint

View full text Add to dashboard Cite

BackgroundThe humoral and cellular immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) upon coronavirus disease 2019 (COVID-19) vaccination remain to be clarified. Hence, we aimed to investigate the chronological changes in SARS-CoV-2 specific IgG antibody, neutralizing antibody, and T cell responses during and after receiving the BNT162b2 vaccine.MethodsWe performed serological, neutralization, and T cell assays among 100 hospital workers aged 22-73 years who received the vaccine. We conducted five surveys on day 1, day 15, day 29 (seven days after the second dose), day 61, and days 82–96 following the first dose.ResultsSARS-CoV-2 spike protein-specific IgG (IgG-S) titers and T cell responses increased significantly following the first vaccination dose. The highest titers were observed on day 29 and decreased gradually until the end of the follow-up period. There was no correlation between IgG-S and T cell responses. Notably, T cell responses were detected on day 15, earlier than the onset of neutralizing activity.ConclusionsThis study demonstrated that both IgG-S and T cell responses were detected before acquiring sufficient levels of SARS-CoV-2 neutralizing antibodies. These early immune responses are sustained for approximately six–ten weeks following the second vaccination dose.

show abstract

Section: P 17supporting

confidence: 86%

“…The quantitative IFN- concentration (IU/mL) was analyzed using the QuantiFERON R&D Analysis Software (version 5.3.0). Greater than or equal to 0.20 IU/mL IFN- concentration was used to define positive T cell responses, as previously reported 14 .…”

Section: Ifn- Whole Blood Assaymentioning

confidence: 99%

SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: A 9 months longitudinal study

Takeuchi

Fukunaga

Yamamoto

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The T-cellular activity was estimated in pre-and post-booster whole blood samples using the Quantiferon SARS-CoV-2 assay (Qiagen, Hilden, Germany [54][55][56] ). In brief, we quantified the interferon (IFN)γ-release after 21-hour incubation of 1 mL heparinized whole blood portions with two different SARS-CoV-2 antigen mixtures (Ag1, Ag2), and with a negative ("Nil") and a mitogen control, using an ELISA (Qiagen).…”

Section: Laboratory Methodsmentioning

confidence: 99%

The comparability of Anti-Spike SARS-CoV-2 antibody tests is time-dependent: a prospective observational study

Perkmann¹,

Mucher²,

Perkmann-Nagele³

et al. 2021

Preprint

View full text Add to dashboard Cite

Objectives Various commercial anti-Spike SARS-CoV-2 antibody tests are used for studies and in clinical settings after vaccination. An international standard for SARS-CoV-2 antibodies has been established to achieve comparability of such tests, allowing conversions to BAU/ml. This study aimed to investigate the comparability of antibody tests regarding the timing of blood collection after vaccination. Methods For this prospective observational study, antibody levels of 50 participants with homologous AZD1222 vaccination were evaluated at 3 and 11 weeks after the first dose and 3 weeks after the second dose using two commercial anti-Spike binding antibody assays (Roche and Abbott) and a surrogate neutralization assay (sVNT). Results The correlation between Roche and Abbott changed significantly depending on the time point studied. Although 3 weeks after the first dose, Abbott provided values three times higher than Roche, 11 weeks after the first dose, the values for Roche were twice as high as for Abbott, and 3 weeks after the second dose even 5-6 times higher. Conclusions The comparability of quantitative anti-Spike SARS-CoV-2 antibody tests is highly dependent on the timing of blood collection after vaccination. Therefore, standardization of the timing of blood collection might be necessary for the comparability of different quantitative SARS-COV-2 antibody assays.

show abstract

“…The advantage of this platform is the workflow is straight forward to follow with tolerance for pause between steps which could accommodate various levels of expertise and diverse clinical/research settings including in low- and middle-income countries. A handful of studies have utilised the QuantiFERON SARS-CoV-2 assay (21–29). A small internal feasibility study carried out by Qiagen found quantifiable responses to vaccination over the course of four weeks after second vaccination (21).…”

Section: Introductionmentioning

confidence: 99%

“…settings including in low-and middle-income countries. A handful of studies have utilised the QuantiFERON SARS-CoV-2 assay (21)(22)(23)(24)(25)(26)(27)(28)(29). A small internal feasibility study carried out by Qiagen found quantifiable responses to vaccination over the course of four weeks after second vaccination (21).…”

mentioning

confidence: 99%

Evaluation of QuantiFERON SARS-CoV-2 interferon-γ release assay following SARS-CoV-2 infection and vaccination

Johnson

Phillips

Adele

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: T cells are important in preventing severe disease from SARS-CoV-2, but scalable and field-adaptable alternatives to expert T cell assays are needed. The interferon-gamma release assay QuantiFERON platform was developed to detect T cell responses to SARS-CoV-2 from whole blood with relatively basic equipment and flexibility of processing timelines. Methods: 48 participants with different infection and vaccination backgrounds were recruited. Whole blood samples were analysed using the QuantiFERON SARS-CoV-2 assay in parallel with the well-established Protective Immunity from T Cells in Healthcare workers (PITCH) ELISpot, which can evaluate spike-specific T cell responses. Aims: The primary aims of this cross-sectional observational cohort study were to establish if the QuantiFERON SARS-Co-V-2 assay could discern differences between specified groups and to assess the sensitivity of the assay compared to the PITCH ELISpot. Findings: The QuantiFERON SARS-CoV-2 distinguished acutely infected individuals (12-21 days post positive PCR) from naive individuals (p< 0.0001) with 100% sensitivity and specificity for SARS-CoV-2 T cells, whilst the PITCH ELISpot had reduced sensitivity (62.5%) for the acute infection group. Sensitivity with QuantiFERON for previous infection was 12.5% (172-444 days post positive test) and was inferior to the PITCH ELISpot (75%). Although the QuantiFERON assay could discern differences between unvaccinated and vaccinated individuals (55-166 days since second vaccination), the latter also had reduced sensitivity (55.5%) compared to the PITCH ELISpot (66.6%). Conclusion: The QuantiFERON SARS-CoV-2 assay showed potential as a T cell evaluation tool soon after SARS-CoV-2 infection but has lower sensitivity for use in reliable evaluation of vaccination or more distant infection.

show abstract

Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently Vaccinated Individuals

Cited by 8 publications

References 16 publications

SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: A 9 months longitudinal study

SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: A 9 months longitudinal study

The comparability of Anti-Spike SARS-CoV-2 antibody tests is time-dependent: a prospective observational study

Evaluation of QuantiFERON SARS-CoV-2 interferon-γ release assay following SARS-CoV-2 infection and vaccination

Contact Info

Product

Resources

About